Drug Trial Radar · NCT06373731
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
313
Actual
Start
May 30, 2024
Primary completion
Aug 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Stealth BioTherapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared.
Conditions
- Age Related Macular Degeneration (ARMD)
Interventions
ElamipretideDrug
Subjects will receive once daily SC doses of 40 mg elamipretide for 96 weeks
PlaceboDrug
Subjects will receive once daily SC doses of Placebo 96 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Week 48 Rate of change in the macular area of photoreceptor lossTime frame: Baseline, Week 48
Locations
53 sites in 8 countries. Site status is shown where the registry gives one.
Associated Retina Consultants
Phoenix, Arizona
Barnet Dulaney Perkins Eye Center
Sun City, Arizona
Retina Associates of Southern California
Huntington Beach, California
Retina Consultants of San Diego
Poway, California
Retinal Consultants Medical Group
Sacramento, California
Orange County Retinal Medical Group
Santa Ana, California
Bay Area Retina Associates
Walnut Creek, California
Retina Consultants of Southern Colorado
Colorado Springs, Colorado
Connecticut Eye Consultants, P.C.
Danbury, Connecticut
Vitreo Retinal Associates
Gainesville, Florida
Florida Retina Institute
Orlando, Florida
Retina Vitreous Associates of Florida
St. Petersburg, Florida
University Retina and Macula Associates
Oak Forest, Illinois
Associated Vitreoretinal and Uveitis Consultants
Carmel, Indiana
Mid Atlantic Retina Specialist
Hagerstown, Maryland
Ophthalmic Consultants of Boston
Boston, Massachusetts
Kellogg Eye Center
Ann Arbor, Michigan
Retina Consultants of Minnesota
Minneapolis, Minnesota
Mid Atlantic Retina
Cherry Hill, New Jersey
NJ Retina
Teaneck, New Jersey
Retina Vitreous Center
Edmond, Oklahoma
Retina Northwest, PC
Portland, Oregon
Retina Research Institute of Texas
Abilene, Texas
Austin Clinical Research, LLC
Austin, Texas
Retina Consultants of Texas
Bellaire, Texas
Valley Retina Institute
McAllen, Texas
Texas Retina Associates of Plano
Plano, Texas
Medical Center Ophthalmology Associates
San Antonio, Texas
Retina Consultants of Texas
The Woodlands, Texas
Emerson Clinical Research Institute
Falls Church, Virginia
Pacific Northwest Retina, PLLC
Silverdale, Washington
Axon Clinical, s.r.o.
Prague, Czechia
Augenzentrum am St. Franziskus-Hospital
Münster, Germany
Klinik und Poliklinik für Augenheilkunde- Universitätsklinik Regensburg
Regensburg, Germany
Department für Augenheilkunde
Tübingen, Germany
University Of Debrecen Eye Center
Debrecen, Hungary
Ganglion Medical Center
Pécs, Hungary
University of Szeged, Department of Ophthalmology
Szeged, Hungary
Hospital Luigi Sacco Ophthalmology Dept
Milan, Italy
IRRCS Ospendale San Raffaele
Milan, Italy
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.